DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.32.2446PMID 21149668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature

  2013cited by this paper
• Age and platelet count are IPSS‐independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival

  2010cited by this paper
• correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBC–transfusion‐dependence

  2010cited by this paper
• Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

  2010cited by this paper
• JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

  2010cited by this paper
• Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients

  2010cited by this paper
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

  2010cited by this paper
• Outcome of transplantation for myelofibrosis.

  2010cited by this paper
• International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

  2010cited by this paper
• A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

  2010cited by this paper
• The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

  2009cited by this paper
• TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

  2009cited by this paper
• Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype

  2009cited by this paper
• Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

  2009cited by this paper
• Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

  2009cited by this paper
• ISCN 2009 - An International System for Human Cytogenetic Nomenclature

  2009cited by this paper
• New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

  2008cited by this paper
• Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

  2008cited by this paper
• Risk factors for leukemic transformation in patients with primary myelofibrosis

  2008cited by this paper
• Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients

  2005cited by this paper
• Pathogenesis of myelofibrosis with myeloid metaplasia.

  2005cited by this paper
• Primary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients

  2001cited by this paper
• Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.

  2001cited by this paper
• Myelofibrosis with myeloid metaplasia.

  2000cited by this paper

• Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

  2026cites this paper
• Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

  2026cites this paper
• Towards Clinically Relevant Immune Biomarkers in Myeloproliferative Neoplasms: Methodological Considerations for Future Studies.

  2026cites this paper
• Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome

  2026cites this paper
• NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance

  2026cites this paper
• Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis.

  2026cites this paper
• Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1

  2026cites this paper
• Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis

  2026cites this paper
• Confronting high-complexity situations in myeloproliferative neoplasms: from treating young patients to TP53-mutated and 'unclassifiable' entities.

  2026cites this paper
• Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays.

  2026cites this paper
• Pre-Hematopoietic Cell Transplant Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.

  2025cites this paper
• Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study

  2025cites this paper
• DIPSS and DIPSS Plus risk scoring in myelofibrosis utilizing automated, electronic health record-integrated decision system

  2025cites this paper
• Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future

  2025cites this paper
• Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia

  2025cites this paper
• CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone)

  2025cites this paper
• SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.

  2025cites this paper
• Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.

  2025cites this paper
• Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping

  2025cites this paper
• Dynamic assessment of myelofibrosis progression in myeloproliferative neoplasm mouse model using a minimally invasive evaluation system.

  2025cites this paper
• Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.

  2025cites this paper
• Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study

  2025cites this paper
• Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.

  2025cites this paper
• Introduction to a How I Treat series on myeloproliferative neoplasms.

  2025cites this paper
• Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience

  2025cites this paper
• Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib

  2025cites this paper
• A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib in Patients with Myelofibrosis who were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single-Arm, Multicenter, Open-Label, Phase Ib Study.

  2025cites this paper
• Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.

  2025cites this paper
• Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models

  2025cites this paper
• Automated risk stratification in myelofibrosis

  2025cites this paper
• Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories.

  2025cites this paper
• Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms.

  2025cites this paper
• Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis

  2025cites this paper
• Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes

  2025influential citation
• Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling

  2025cites this paper
• Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report

  2025cites this paper
• Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression

  2025cites this paper
• Efficacy and tolerability of ruxolitinib in Egyptian patients with intermediate and high-risk myelofibrosis: a single center study

  2025cites this paper
• Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adults

  2025cites this paper
• Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes

  2025cites this paper
• Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML

  2025cites this paper
• Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations

  2025cites this paper
• AI predicts a high risk in transplantation for myelofibrosis

  2025cites this paper
• 芦可替尼治疗不同年龄分层骨髓纤维化患者的疗效及预后因素分析

  2025cites this paper
• Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib

  2025cites this paper
• Landscape of somatic mutations in myeloproliferative neoplasm in Pakistani population

  2025cites this paper
• Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)

  2025cites this paper
• Myelofibrosis: Timing of Transplantation and Management of Splenomegaly.

  2025cites this paper
• Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design

  2025influential citation
• Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates

  2025cites this paper
• Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases

  2025cites this paper
• Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy

  2025cites this paper
• Risk Stratification Using DIPSS and Splenomegaly in Myelofibrosis Treated with Pre-Transplant JAK inhibitors.

  2025cites this paper
• EXABS-115-MPN: Predictive Markers for Ruxolitinib in Myelofibrosis

  2025cites this paper
• Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems

  2025cites this paper
• Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.

  2025cites this paper
• Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples

  2025cites this paper
• From symptom scales to regulatory endpoints: the evolution and clinical impact of patient-reported outcome measures in myeloproliferative neoplasms

  2025cites this paper
• Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs)

  2025cites this paper
• Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis

  2025cites this paper
• Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis

  2025influential citation
• 伴NFE2基因突变骨髓增殖性肿瘤患者的临床和分子生物学特征分析

  2025cites this paper
• Momelotinib – a tale of trials, tribulations, transfusion independence, and triumph

  2025cites this paper
• Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.

  2025cites this paper
• Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib

  2025cites this paper
• Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1‐Positive and ‐Negative Myeloproliferative Neoplasms

  2025cites this paper
• Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib

  2025cites this paper
• Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry

  2025cites this paper
• Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

  2025cites this paper
• Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

  2024cites this paper
• Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study

  2024cites this paper
• Pathogenesis and management of high molecular risk myeloproliferative neoplasms

  2024cites this paper
• Genetic and immunologic features associated with thrombocytopenia progression and poor prognosis in patients with myelofibrosis

  2024cites this paper
• Treatment Strategies Used in Treating Myelofibrosis: State of the Art

  2024cites this paper
• When and how to transplant in myelofibrosis – recent trends

  2024influential citation
• Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis

  2024cites this paper
• Current myeloproliferative neoplasm scoring systems for clinical practice.

  2024cites this paper
• Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib

  2024cites this paper
• Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival

  2024cites this paper
• Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia

  2024cites this paper
• JAK Inhibitors for Myelofibrosis: Strengths and Limitations

  2024cites this paper
• Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis—insights from a multicenter study

  2024cites this paper
• Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?

  2024cites this paper
• The role of corticosteroids in the current treatment paradigm for myelofibrosis

  2024cites this paper
• A comparative retrospective study of pre-fibrotic primary myelofibrosis versus overtly fibrotic stage in Qatar: clinicopathological, genetic landscape, risk stratification and survival data (2008–2021) – a single center experience

  2024cites this paper
• Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

  2024cites this paper
• Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis

  2024cites this paper
• SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia.

  2024cites this paper
• Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study

  2024cites this paper
• Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Myeloproliferative Neoplasms

  2024cites this paper
• Identifying disease-modifying potential in myelofibrosis clinical trials.

  2024cites this paper
• Induction of remission after donor lymphocyte infusion following allogeneic transplant in a case of pediatric primary myelofibrosis

  2024cites this paper
• Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives

  2024cites this paper
• Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study

  2024cites this paper
• Myelofibrosis and allogeneic transplantation: critical points and challenges

  2024cites this paper
• Prognostic and Predictive Models in Myelofibrosis

  2024cites this paper
• Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

  2024cites this paper
• Advances in Stem Cell Transplantation for Myelofibrosis

  2024cites this paper
• Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis

  2024cites this paper
• Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment

  2024cites this paper